News | November 09, 2023
Biocon Biologics announces divestment of two non-core branded formulations
Total transaction value of the divestment is Rs. 3,660 million
Total transaction value of the divestment is Rs. 3,660 million
This project will aim to develop a next-generation A3 adenosine receptor drug agonists
Biologics manufacturing to expand the Aragen platform by offering “gene to GMP” solution
2023 Nobel laureates discovered how pseudouridine could make mRNA suitable for vaccines
Nanoform will receive access to compound libraries and large data sets to undertake STARMAP screening
Three block copolymers added to RESOMER portfolio of bioabsorbable polymers
Tagrisso is projected to be a pivotal contributor to AstraZeneca’s portfolio
The super-resolution optical technology will accelerate discovery in biomedical research and transform in vitro diagnostics
The VitalDose Drug Delivery Platform has been used in patient-centric dose forms in women’s health for over two decades
In 2030 over 50% of FDA approvals will involve AI discovered and developed drugs
Subscribe To Our Newsletter & Stay Updated
